Septerna (NASDAQ:SEPN) Releases Earnings Results

Key Points

• Septerna (NASDAQ:SEPN) reported earnings of ($0.56) per share, significantly missing analysts' expectations of ($0.05).
• The company's stock fell 1.7% to $11.49, with a 1-year price range of $4.17 to $28.99.
• Analyst ratings are generally positive, with a consensus of "Moderate Buy" and a target price of $26.75.

Septerna (NASDAQ:SEPN - Get Free Report) issued its earnings results on Monday. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51), Zacks reports.

Septerna Stock Down 1.7%

SEPN traded down $0.20 during midday trading on Monday, hitting $11.49. 117,902 shares of the company were exchanged, compared to its average volume of 205,452. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99. The firm's 50 day moving average price is $11.41 and its 200-day moving average price is $9.24.

Analyst Ratings Changes

A number of brokerages have weighed in on SEPN. Cantor Fitzgerald raised their target price on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, May 16th. HC Wainwright assumed coverage on Septerna in a report on Monday, June 23rd. They set a "buy" rating and a $26.00 price objective on the stock. Finally, Wells Fargo & Company raised their price objective on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $26.75.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Woodline Partners LP increased its position in Septerna by 94.2% in the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company's stock valued at $3,373,000 after buying an additional 282,585 shares in the last quarter. Rhumbline Advisers increased its position in Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company's stock valued at $135,000 after buying an additional 3,323 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Septerna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company's stock valued at $5,158,000 after buying an additional 78,316 shares in the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.